Eisai Plans R&D Revamp To Turn The Development Tide
This article was originally published in The Pink Sheet Daily
Executive Summary
Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.
You may also be interested in...
Post-Aricept Patent Expiry, Eisai Starts Comeback With Roll-Out Of New Anti-Epileptic Fycompa In Europe
Eisai hopes the launch of its first-in-class anti-epileptic drug Fycompa in Britain and other European markets will help offset revenues lost after its Aricept Alzheimer’s therapy went off patent in the region earlier this year, and signal a new phase of growth for the Japanese company.
Eisai Sees Generics Opportunity In Japan For Innovator Companies
A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito
Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
TOKYO - Eisai registered swift benefits from its acquisition of MGI Pharma with oncology revenues accounting for 10 percent of its global sales, Eisai CEO Haruo Naito told an Oct. 31 earnings conference